A dibenzylamine compound represented by the formula (1)
wherein R
1
and R
2
are each a C
1-6
alkyl group optionally substituted by halogen atoms and the like; R
3
, R
4
and R
5
are each a hydrogen atom, a halogen atom and the like, or R
3
and R
4
may form, together with carbon atoms bonded thereto, a homocyclic or heterocyclic ring optionally having substituent(s); A is
—N(R
7
) (R
8
) and the like; ring B is an aryl group or a heterocyclic residue; R
6
is a hydrogen atom, a halogen atom, a nitro group, a C
1-6
alkyl group and the like; n is an integer of 1 to 3, a prodrug thereof and a pharmaceutically acceptable salt thereof show selective and potent CETP inhibitory activity, and therefore, they can be provided as therapeutic or prophylactic agents for hyperlipidemia or arteriosclerosis and the like.
Nitrogen-containing fused ring compounds and use thereof
申请人:Hirata Kazuyuki
公开号:US20070010670A1
公开(公告)日:2007-01-11
A URAT1 activity inhibitor containing a nitrogen-containing fused ring compound represented by the following formula [1]:
wherein each symbol is as defined in the description. The present invention is useful for the prophylaxis or treatment of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like.
[EN] HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS GAMMA-T DU RÉCEPTEUR ORPHELIN APPARENTÉ AUX RÉCEPTEURS DES RÉTINOÏDES (ROR) )
申请人:TAKEDA PHARMACEUTICAL
公开号:WO2016002968A1
公开(公告)日:2016-01-07
Provided are heterocyclic compounds having a RORγt inhibitory action represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
The present invention relates to an ester represented by the formula [1]:
or its pharmaceutically acceptable salt, or use of the same. The compound represented by the formula [1] or its pharmaceutically acceptable salt is useful as an agent for the treatment or prophylaxis of hyperlipidemia or the like, since it disappears very rapidly in the living body and has an excellent MTP inhibitory activity.
The present invention provides a compound represented by the following formula [1′] or a salt thereof:
wherein ring A, R
2
, R
3
, R
4
and X are as defined in the description, and an agent for the treatment or prophylaxis of a pathology involving glucocorticoid, or a 11βHSD1 inhibitor, containing the compound or a salt thereof.